Send the following on WhatsApp
Continue to Chat降糖和減重療效顯著:信達生物宣佈Mazdutide(IBI362) 在中國2型糖尿病受試者中的II期臨床研究達到主要終點 https://geneonline.news/%e9%99%8d%e7%b3%96%e5%92%8c%e6%b8%9b%e9%87%8d%e7%99%82%e6%95%88%e9%a1%af%e8%91%97%ef%bc%9a%e4%bf%a1%e9%81%94%e7%94%9f%e7%89%a9%e5%ae%a3%e4%bd%88mazdutideibi362-%e5%9c%a8%e4%b8%ad%e5%9c%8b2%e5%9e%8b/